Direct pharmacological targeting of Piezo1 by Paeoniflorin: a novel therapeutic approach for renal fibrosis.

["Li R", "Xia J", "Shi C", "Zhang K", "Qu Y", "He G", "Fu Z", "Deng L", "Liu R", "Wang X"]
Journal of advanced research 2026
Open on PubMed

BACKGROUND: Renal fibrosis-characterized by microcirculatory disturbances and endothelial-mesenchymal transition (EndMT)-is a major pathological feature of chronic kidney disease (CKD) and remains a significant therapeutic challenge. The mechanosensitive ion channel Piezo1 plays a pivotal role in endothelial mechanotransduction and has been implicated in fibrogenesis, yet specific pharmacological interventions targeting Piezo1 are lacking. METHODS: We evaluated the renoprotective effects of paeoniflorin (PF), a bioactive monoterpene glycoside, in 5/6 nephrectomy-induced chronic renal failure (CRF) rats and diabetic kidney disease (DKD) db/db mice. PF-Piezo1 interactions were characterized using molecular docking, surface plasmon resonance (SPR), and functional assays. In vitro studies employing models of matrix stiffness, endothelial-fibroblast crosstalk, and HIF-1α inhibition were performed to elucidate the underlying mechanisms. RESULTS: PF treatment preserved renal function, reduced glomerulosclerosis, and ameliorated microvascular rarefaction in both CRF and DKD. Molecular docking and SPR analyses revealed that PF binds Piezo1 with high affinity, thereby inhibiting Yoda1-induced Ca2+ influx and attenuating stiffness-induced EndMT. PF restored the expression of endothelial markers including VE-cadherin and eNOS, and suppressed HIF-1α-mediated upregulation of Vimentin and TGF-β1. Moreover, co-culture experiments demonstrated that PF disrupted endothelial-derived TGF-β1 paracrine signaling, reducing fibroblast activation and extracellular matrix deposition. Notably, Piezo1 knockdown or HIF-1α inhibition recapitulated the dual effects of PF on endothelial restoration and fibrosis suppression. CONCLUSIONS: Our findings indicate that PF exerts renoprotective effects by targeting the Piezo1/Ca2+/HIF-1α axis, thereby mitigating renal fibrosis. By interrupting pathological endothelial-fibroblast communication and restoring microvascular integrity, PF represents a promising mechanotherapeutic strategy for CKD.

9 Figures Extracted
Figure 1
Figure 1 PMC
Fig. 1
Fig. 1 PMC
PF exhibits renoprotective effects in models of renal dysfunction (A) Schematic of experimental design. Sprague-Dawley (SD) rats were divided into fou...
Fig. 2
Fig. 2 PMC
PF attenuates renal fibrosis progression in experimental CKD models (A) Representative Masson’s trichrome staining of glomeruli. Blue staining indicat...
Fig. 3
Fig. 3 PMC
Systems pharmacology reveals hemodynamic and endothelial remodeling mechanisms of PF in alleviating microcirculatory dysfunction during CRF (A–B) KEGG...
Fig. 4
Fig. 4 PMC
PF restores microvascular integrity via hemodynamic improvement and vascular repair (A) Renal Doppler ultrasound images. CRF rats exhibited reduced re...
Fig. 5
Fig. 5 PMC
PF effectively improves endothelial function (A) Hypoxia (1 % O 2 )-impaired HUVEC proliferation (CCK-8 assay) was rescued by PF (400 μM) at 48 h (n =...
Fig. 6
Fig. 6 PMC
PF attenuates Yoda1-induced Ca 2+ influx via functional modulation of Piezo1 channels (A) Immunofluorescence co-localization of Piezo1 (green) and PE...
Fig. 7
Fig. 7 PMC
PF inhibits matrix stiffness-induced acceleration of EndMT through Piezo1 activation (A–F) Matrix stiffness-dependent protein modulation in HUVECs. HU...
Fig. 8
Fig. 8 PMC
PF inhibits EndMT through the Piezo1-mediated HIF-1α signaling pathway (A–C) Renal HIF-1α expression analysis. (A) Representative RT-qPCR analysis of ...